Rocket Pharmaceuticals, Inc. (RCKT) Investor Relations Documents

Rocket Pharmaceuticals, Inc. (RCKT) investor relations documents from the company's IR site: 1 presentation, 15 press releases; latest deck 2026-08-10. Read in-app with summaries. First-party data.

Rocket Corporate Presentation: Rocket Pharmaceuticals is a cardiovascular-focused gene therapy company with $283.7M in cash, funding operations into Q2 2028.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-10PresentationRocket Corporate Presentation
2026-08-10Press releaseRocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
2026-08-03Press releaseRocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under
2026-06-12Press releaseRocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
2026-05-28Press releaseRocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-07Press releaseRocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
2026-04-28Press releaseRocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
2026-03-27Press releaseRocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficie
2026-02-26Press releaseRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
2026-02-23Press releaseRocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-01-05Press releaseRocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Press releaseRocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Press releaseRocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
Press releaseRocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
Press releaseRocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights
Press releaseRocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease

RCKT overview · RCKT earnings · RCKT financials · RCKT KPIs · RCKT ownership · RCKT peers · RCKT filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.